Derrick W. Su, MD
Specialist
- Medicare participating
At a glance
- Medical school
- Boston University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 145
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Boston University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
CA license A125217
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
- Providence Mission Hospital Mission Viejo, CA
- Memorialcare Saddleback Medical Center Laguna Hills, CA
- Memorialcare Orange Coast Medical Center Fountain Valley, CA
Medical groups
- Los Angeles Hematology-Oncology Medical Group (50 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 145
- Services billed
- 71,343
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, dexamethasone sodium phosphate, 1 mg | 1,020 | 15 |
| Injection, ondansetron hydrochloride, per 1 mg | 712 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 293 | 104 |
| Administration of chemotherapy into vein, 1 hour or less | 167 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 163 | 61 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 122 | 17 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 95 | 36 |
| Administration of additional new drug or substance into vein, 1 hour or less | 91 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 23 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 97 |
| Eliquis (apixaban) Other prescribers in Fountain Valley, CA | 77 |
| Hydroxyurea Other prescribers in Fountain Valley, CA | 72 |
| Anastrozole Other prescribers in Fountain Valley, CA | 70 |
| Procrit (epoetin alfa) | 47 |
| Letrozole Other prescribers in Fountain Valley, CA | 41 |
| Prednisone Other prescribers in Fountain Valley, CA | 39 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Fountain Valley, CA | 36 |
| Diphenhydramine Hcl | 36 |
| Lenalidomide | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 64 companies reported 390 payments worth $10,310 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,487 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $581 |
| Merck Sharp & Dohme LLC | $458 |
| AbbVie Inc. | $448 |
| Janssen Biotech, Inc. | $418 |
| Pfizer Inc. | $382 |
| Eisai Inc. | $339 |
| GlaxoSmithKline, LLC. | $308 |
| Food and Beverage | $9,277 |
|---|---|
| Long term medical supply or device loan | $1,000 |
| Education | $32.72 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Amgen Inc. Sep 25, 2025 | Education in-kind | $32.72 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.